Suppr超能文献

慢性非传染性炎症性皮肤病中未满足的医疗需求。

Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

作者信息

Ujiie Hideyuki, Rosmarin David, Schön Michael P, Ständer Sonja, Boch Katharina, Metz Martin, Maurer Marcus, Thaci Diamant, Schmidt Enno, Cole Connor, Amber Kyle T, Didona Dario, Hertl Michael, Recke Andreas, Graßhoff Hanna, Hackel Alexander, Schumann Anja, Riemekasten Gabriela, Bieber Katja, Sprow Gant, Dan Joshua, Zillikens Detlef, Sezin Tanya, Christiano Angela M, Wolk Kerstin, Sabat Robert, Kridin Khalaf, Werth Victoria P, Ludwig Ralf J

机构信息

Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Department of Dermatology, Tufts Medical Center, Boston, MA, United States.

出版信息

Front Med (Lausanne). 2022 Jun 9;9:875492. doi: 10.3389/fmed.2022.875492. eCollection 2022.

Abstract

An estimated 20-25% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.

摘要

据估计,20%-25%的人口受慢性非传染性炎症性皮肤病影响。慢性皮肤炎症有多种病因。在最常见的慢性炎症性皮肤病中,特应性皮炎、银屑病、荨麻疹、扁平苔藓和化脓性汗腺炎是由遗传和环境因素的复杂相互作用所致。自身免疫是慢性皮肤炎症的另一个重要原因。自身免疫反应可能主要由T细胞驱动,如斑秃或白癜风,或在慢性自发性荨麻疹、天疱疮和类天疱疮疾病中由B细胞驱动。慢性皮肤炎症的罕见病因是自身炎症性疾病或风湿性疾病,如皮肤红斑狼疮或皮肌炎。虽然我们在诊断和治疗方面有了显著改善,但仍存在一些挑战。特别是对于慢性皮肤炎症的罕见病因,由于认识不足和缺乏诊断方法,早期诊断常常被漏诊。全身免疫抑制是几乎所有这些疾病的首选治疗方法。免疫抑制引起的不良事件、治疗反应不足和复发仍然是一个挑战。对于特应性皮炎和银屑病,已经开发了广泛的创新治疗方法。然而,目前还无法预测治疗反应。因此,需要开发能够为个体患者选择特定药物的(生物)标志物。鉴于过去几年令人鼓舞的进展,我们预计慢性炎症性皮肤病诊断和治疗中的许多此类挑战将在未来得到彻底解决。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2326/9218547/d279c26cbbe7/fmed-09-875492-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验